(PDYN) Palladyne AI - Overview
Stock: Palladyne IQ, Palladyne Pilot
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 162% |
| Relative Tail Risk | -25.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.27 |
| Alpha | -42.17 |
| Character TTM | |
|---|---|
| Beta | 1.873 |
| Beta Downside | 1.064 |
| Drawdowns 3y | |
|---|---|
| Max DD | 87.81% |
| CAGR/Max DD | 0.28 |
Description: PDYN Palladyne AI December 31, 2025
Palladyne AI Corp. (NASDAQ: PDYN) develops AI/ML software that upgrades third-party stationary and mobile robots-both industrial arms and UAVs-so they can perceive, learn, and act in real-time without heavy cloud dependence or extensive re-programming. Its flagship offerings include Palladyne IQ for industrial robots/cobots and Palladyne Pilot for Class 1 drones, which fuse multi-modal sensor data to maintain persistent situational awareness across fleets. The firm serves a breadth of U.S. end-markets, notably manufacturing, defense, infrastructure, energy, and aerospace, and rebranded from Sarcos Technology & Robotics in March 2024.
From external data (as of Q3 2024), the global industrial robotics market is expanding at ~12% YoY, driven by a shortage of skilled labor and the push for “lights-out” factories; AI-enabled robots now capture roughly 30% of new robot spend, up from 22% in 2022. Palladyne’s latest 10-K (filed 30 Sep 2024) disclosed $18.7 M in revenue-a 45% increase year-over-year-while R&D expense rose to 22% of sales, reflecting its focus on on-edge inference capabilities. A key macro driver is the U.S. Defense Authorization Act FY 2025, which earmarks $1.2 B for autonomous systems, potentially expanding demand for Palladyne’s defense-related solutions.
If you want a data-rich, third-party perspective on PDYN’s valuation and risk profile, a quick look at ValueRay’s analyst dashboard can help you fill in the gaps.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -41.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.34 > 0.02 and ΔFCF/TA 53.81 > 1.0 |
| NWC/Revenue: 1290 % < 20% (prev 254.5%; Δ 1035 % < -1%) |
| CFO/TA -0.33 > 3% & CFO -24.2m > Net Income -41.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (40.5m) vs 12m ago 54.66% < -2% |
| Gross Margin: 57.62% > 18% (prev 0.48%; Δ 5713 % > 0.5%) |
| Asset Turnover: 7.78% > 50% (prev 20.06%; Δ -12.28% > 0%) |
| Interest Coverage Ratio: -1.56 > 6 (EBITDA TTM -24.4m / Interest Expense TTM 16.2m) |
Altman Z'' -15.00
| A: 0.77 (Total Current Assets 60.5m - Total Current Liabilities 4.46m) / Total Assets 72.9m |
| B: -6.57 (Retained Earnings -479.3m / Total Assets 72.9m) |
| C: -0.45 (EBIT TTM -25.2m / Avg Total Assets 55.8m) |
| D: -22.73 (Book Value of Equity -479.3m / Total Liabilities 21.1m) |
| Altman-Z'' Score: -43.29 = D |
Beneish M -3.49
| DSRI: 1.75 (Receivables 2.15m/2.20m, Revenue 4.35m/7.77m) |
| GMI: 0.84 (GM 57.62% / 48.22%) |
| AQI: 0.37 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 0.56 (Revenue 4.35m / 7.77m) |
| TATA: -0.24 (NI -41.4m - CFO -24.2m) / TA 72.9m) |
| Beneish M-Score: -3.49 (Cap -4..+1) = AA |
What is the price of PDYN shares?
Over the past week, the price has changed by +9.82%, over one month by +23.02%, over three months by +5.92% and over the past year by -21.75%.
Is PDYN a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the PDYN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9 | 25.7% |
| Analysts Target Price | 9 | 25.7% |
| ValueRay Target Price | 6.3 | -11.6% |
PDYN Fundamental Data Overview February 04, 2026
P/S = 70.1607
P/B = 5.6182
Revenue TTM = 4.35m USD
EBIT TTM = -25.2m USD
EBITDA TTM = -24.4m USD
Long Term Debt = 10.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 976.0k USD (from shortTermDebt, last quarter)
Debt = 10.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -17.2m USD (from netDebt column, last quarter)
Enterprise Value = 258.0m USD (304.9m + Debt 10.2m - CCE 57.1m)
Interest Coverage Ratio = -1.56 (Ebit TTM -25.2m / Interest Expense TTM 16.2m)
EV/FCF = -10.42x (Enterprise Value 258.0m / FCF TTM -24.8m)
FCF Yield = -9.60% (FCF TTM -24.8m / Enterprise Value 258.0m)
FCF Margin = -569.6% (FCF TTM -24.8m / Revenue TTM 4.35m)
Net Margin = -953.5% (Net Income TTM -41.4m / Revenue TTM 4.35m)
Gross Margin = 57.62% ((Revenue TTM 4.35m - Cost of Revenue TTM 1.84m) / Revenue TTM)
Gross Margin QoQ = 46.40% (prev 53.30%)
Tobins Q-Ratio = 3.54 (Enterprise Value 258.0m / Total Assets 72.9m)
Interest Expense / Debt = 8.57% (Interest Expense 874.0k / Debt 10.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -19.9m (EBIT -25.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.56 (Total Current Assets 60.5m / Total Current Liabilities 4.46m)
Debt / Equity = 0.20 (Debt 10.2m / totalStockholderEquity, last quarter 51.8m)
Debt / EBITDA = 0.70 (negative EBITDA) (Net Debt -17.2m / EBITDA -24.4m)
Debt / FCF = 0.69 (negative FCF - burning cash) (Net Debt -17.2m / FCF TTM -24.8m)
Total Stockholder Equity = 31.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -74.22% (Net Income -41.4m / Total Assets 72.9m)
RoE = -133.2% (Net Income TTM -41.4m / Total Stockholder Equity 31.1m)
RoCE = -61.13% (EBIT -25.2m / Capital Employed (Equity 31.1m + L.T.Debt 10.2m))
RoIC = -64.11% (negative operating profit) (NOPAT -19.9m / Invested Capital 31.1m)
WACC = 12.62% (E(304.9m)/V(315.1m) * Re(12.82%) + D(10.2m)/V(315.1m) * Rd(8.57%) * (1-Tc(0.21)))
Discount Rate = 12.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 25.08%
Fair Price DCF = unknown (Cash Flow -24.8m)
EPS Correlation: -4.58 | EPS CAGR: 2.39% | SUE: 0.15 | # QB: 0
Revenue Correlation: -31.71 | Revenue CAGR: -4.04% | SUE: -0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=+0.090 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.41 | Chg30d=+0.280 | Revisions Net=-1 | Growth EPS=-441.7% | Growth Revenue=+467.1%